Molnupiravir doesn't reduce COVID-19 hospitalisations in high-risk vaccinated people

Published on December 23, 2022

Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community. 
Continue reading on website
Other news

Five reasons to consider an MBA

December 22, 2022
From career change to new skills and better pay and rewards, as well as doing good for society – where are your career ambitions as we step into a new year? We meet a few Cambridge MBA graduates and hear how an MBA changed their career pathway. You want a career changeRachel Buchholtzer (MBA 2021)“I was interested in working in finance when I started my MBA, but I didn’t really think it was a via

Poets & Quants: ‘A tremendous opportunity to make positive change’: b-school deans share 2023 resolutions

December 27, 2022
Cambridge Judge Business School is featured in this article about B-school deans sharing resolutions for 2023.Read the full article [poetsandquants.com]The post Poets & Quants: ‘A tremendous opportunity to make positive change’: b-school deans share 2023 resolutions appeared first on Cambridge Judge Business School.